Literature DB >> 32146345

Application of CT-based radiomics in predicting portal pressure and patient outcome in portal hypertension.

Yujen Tseng1, Lili Ma2, Shaobo Li3, Tiancheng Luo4, Jianjun Luo5, Wen Zhang5, Jian Wang4, Shiyao Chen6.   

Abstract

PURPOSE: Portal venous pressure (PVP) measurement is of clinical significance, especially in patients with portal hypertension. However, the invasive nature and associated complications limits its application. The aim of the study is to propose a noninvasive predictive model of PVP values based on CT-extracted radiomic features.
METHODS: Radiomics PVP (rPVP) models based on liver, spleen and combined features were established on an experimental cohort of 169 subjects. Radiomics features were extracted from each ROI and reduced via the LASSO regression to achieve an optimal predictive formula. A validation cohort of 62 patients treated for gastroesophageal varices (GOV) was used to confirm the utility of rPVP in predicting variceal recurrence. The association between rPVP and response to treatment was observed.
RESULTS: Three separate predictive formula for PVP were derived from radiomics features. rPVP was significantly correlated to patient response to endoscopic treatment for GOV. Among which, the model containing both liver and spleen features has the highest predictability of variceal recurrence, with an optimal cut-off value at 29.102 mmHg (AUC 0.866). A Kaplan Meier analysis further confirmed the difference between patients with varying rPVP values.
CONCLUSION: PVP values can be accurately predicted by a non-invasive, CT derived radiomics model. rPVP serves as a non-invasive and precise reference for predicting treatment outcome for GOV secondary to portal hypertension.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Esophageal and gastric varices; Portal hypertension; Portal venous pressure; Radiomics

Mesh:

Year:  2020        PMID: 32146345     DOI: 10.1016/j.ejrad.2020.108927

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  7 in total

Review 1.  Noninvasive imaging assessment of portal hypertension.

Authors:  Paul Kennedy; Octavia Bane; Stefanie J Hectors; Aaron Fischman; Thomas Schiano; Sara Lewis; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2020-09-14

Review 2.  Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease.

Authors:  Jérémy Dana; Aïna Venkatasamy; Antonio Saviano; Joachim Lupberger; Yujin Hoshida; Valérie Vilgrain; Pierre Nahon; Caroline Reinhold; Benoit Gallix; Thomas F Baumert
Journal:  Hepatol Int       Date:  2022-02-09       Impact factor: 9.029

Review 3.  Artificial intelligence in the diagnosis of cirrhosis and portal hypertension.

Authors:  Xiaoguo Li; Ning Kang; Xiaolong Qi; Yifei Huang
Journal:  J Med Ultrason (2001)       Date:  2021-11-17       Impact factor: 1.878

4.  A novel radiomics-platelet nomogram for the prediction of gastroesophageal varices needing treatment in cirrhotic patients.

Authors:  Yiken Lin; Lijuan Li; Dexin Yu; Zhuyun Liu; Shuhong Zhang; Qiuzhi Wang; Yueyue Li; Baoquan Cheng; Jianping Qiao; Yanjing Gao
Journal:  Hepatol Int       Date:  2021-06-11       Impact factor: 6.047

5.  Spleen Radiomics Signature: A Potential Biomarker for Prediction of Early and Late Recurrences of Hepatocellular Carcinoma After Resection.

Authors:  Pinxiong Li; Lei Wu; Zhenhui Li; Jiao Li; Weitao Ye; Zhenwei Shi; Zeyan Xu; Chao Zhu; Huifen Ye; Zaiyi Liu; Changhong Liang
Journal:  Front Oncol       Date:  2021-08-13       Impact factor: 6.244

6.  Computed Tomography-Based Texture Features for the Risk Stratification of Portal Hypertension and Prediction of Survival in Patients With Cirrhosis: A Preliminary Study.

Authors:  Shang Wan; Yi Wei; Xin Zhang; Caiwei Yang; Fubi Hu; Bin Song
Journal:  Front Med (Lausanne)       Date:  2022-04-01

Review 7.  Radiomics in liver diseases: Current progress and future opportunities.

Authors:  Jingwei Wei; Hanyu Jiang; Dongsheng Gu; Meng Niu; Fangfang Fu; Yuqi Han; Bin Song; Jie Tian
Journal:  Liver Int       Date:  2020-07-02       Impact factor: 5.828

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.